Generic drugmaker Laurus Labs Board will invest ₹83.30 crore in its joint venture with Slovenian firm KRKA.
Consequently, KRKA will also be investing ₹86.7 crore to maintain the existing shareholding ratio of 51:49 in KRKA Pharma, the joint venture company, Laurus said on Thursday in a filing after getting its Board approval for the ₹83.30 crore investment.
The purpose of the investment is to acquire land and to meet initial cost of setting up a manufacturing facility for production of finished products for the new markets, including the Indian market. This investment aligns with the company’s strategic growth plans and long-term business objectives, it said.
Laurus said the proposed investment in the JV is expected to be completed this month. KRKA Pharma was incorporated in 2024 and is yet to commence business operations.
Published – March 06, 2025 09:19 pm IST